

## Cancer and Genetics: Part II

Prepared by Martha Weinar, MS, RN, and Debra Mercy, MS, CRNP, AOCN®

### Microarray Technology

- Bertucci, F., Houlgatte, R., Nguyen, C., Viens, P., Jordan, B.R., & Birnbaum, D. (2001). Gene expression profiling of cancer by use of DNA arrays: How far from the clinic? *Lancet Oncology*, 2, 674–682.
- Bowtell, D.D.L. (1999). Options available—from start to finish—for obtaining expression data by microarray. *Nature Genetics*, 21(Suppl. 1), 25–32.
- Lockhart, D.J., & Winzler, E.A. (2000). Genomics, gene expression and DNA arrays. *Nature*, 405, 827–836.
- Macoska, J.A. (2002). The progressing clinical utility of DNA microarrays. *CA: A Cancer Journal for Clinicians*, 52, 50–59.
- Marshall, E. (1999). Do-it-yourself gene watching. *Science*, 286, 444–447.
- Marx, J. (2000). DNA arrays reveal cancer in its many forms. *Science*, 289, 1670–1672.
- Ramaswamy, S., & Golub, T.R. (2002). DNA microarrays in clinical oncology. *Journal of Clinical Oncology*, 20, 1932–1941.
- Shi, L. (2002). DNA microarray—A technology that is reshaping molecular biology. Retrieved October 11, 2003, from <http://www.gene-chips.com>
- Sinclair, A. (2002). Genetics 101: Detecting mutations in human genes. *Canadian Medical Association Journal*, 167, 275–279.
- Tefferi, A., Bolander, M.E., Ansell, S.M., Wieben, E.D., & Spelsberg, T.C. (2002). Primer on medical genomics part III: Microarray experiments and data analysis. *Mayo Clinic Proceedings*, 77, 927–940.
- Vastag, B. (2003). Gene chips inch toward the clinic. *JAMA*, 289, 155–159.

### Molecular Carcinogenesis of Cancer

- Cahill, D.P., Lengauer, C., Yu, J., Riggins, G.J., Willson, J.K., Markowitz, S.D., et al. (1998). Mutations of mitotic checkpoint genes in human cancers. *Nature*, 392, 300–303.
- Cama, A., Genuardi, M., Guanti, G., Radice, P., & Varesco, L. (1996). Molecular genetics of hereditary non-polyposis colorectal cancer (HNPPC). *Tumori*, 82, 122–135.

- El-Rifai, W., & Powell, S.M. (2002). Molecular biology of gastric cancer. *Seminars in Radiation Oncology*, 12, 128–140.
- Fabjani, G., Kucera, E., Schuster, E., Minai-Pour, M., Czerwenka, K., Sliutz, G., et al. (2002). Genetic alterations in endometrial hyperplasia and cancer. *Cancer Letters*, 175, 205–211.
- Fearon, E.R., & Dang, C.V. (1999). Tumor suppressor meets oncogene. *Current Biology*, 9, R62–R65.
- Hanahan, D., & Weinberg, R.A. (2000). The hallmarks of cancer. *Cell*, 100, 57–70.
- Hussain, S.P., Hofseth, L.J., & Harris, C.C. (2001). Tumor suppressor genes: At the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. *Lung Cancer*, 34(Suppl. 2), S7–S15.
- Jazaeri, A.A., Lu, K., Schmandt, R., Harris, C.P., Rao, P.H., Sotiriou, C., et al. (2003). Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. *Molecular Carcinogenesis*, 36, 53–59.
- Knudson, A.G. (1996). Hereditary cancer: Two hits revisited. *Journal of Cancer Research and Clinical Oncology*, 122, 135–140.
- Latchman, D.S. (1996). Mechanisms of disease: Transcription-factor mutations and disease. *New England Journal of Medicine*, 334, 28–33.
- Lengauer, C., Kinzler, K.W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. *Nature*, 396, 643–649.
- Luo, J.H., Yu, Y.P., Cieply, K., Lin, F., DeFlavia, P., Dhir, R., et al. (2002). Gene expression and analysis of prostate cancers. *Molecular Carcinogenesis*, 33, 25–35.
- Orr-Weaver, T.L., & Weinberg, R.A. (1998). A checkpoint on the road to cancer. *Nature*, 392, 223–224.
- Prasad, K.N., Hovland, A.R., Nahreini, P., Cole, W., Hovland, P., Kumar, B., et al. (2001). Differentiation genes: Are they primary targets for human carcinogenesis? *Experimental Biology and Medicine*, 226, 805–813.
- Uys, P., & Helden, P.D. (2003). On the nature of genetic changes required for the development of esophageal cancer. *Molecular Carcinogenesis*, 36, 82–89.

- van de Vijver, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A.M., Voskuil, D.W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. *New England Journal of Medicine*, 347, 1999–2009.
- Wang, X.W., & Harris, C.C. (1997). P53 tumor-suppressor gene: Clues to molecular carcinogenesis. *Journal of Cell Physiology*, 173, 247–255.
- Weinberg, R.A. (1994). Oncogenes and tumor suppressor genes. *CA: A Cancer Journal for Clinicians*, 44, 160–170.
- Weinberg, R.A. (1996). How cancer arises. *Scientific American*, 275(3), 62–71.

### Molecular Characteristics as Prognostic Indicators

- Chang, J., Clark, G.M., Allred, D.C., Mohsin, S., Chamness, G., & Elledge, R.M. (2003). Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. *Cancer*, 97, 545–553.
- Dürig, J., Nüchel, H., Hütman, A., Kruse, E., Hölter, T., Halfmeyer, K., et al. (2002). Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. *Blood*, 101, 2748–2755.
- Esteva, F.J., Sahin, A.A., Cristofanilli, M., Arun, B., & Hortobagyi, G.N. (2002). Molecular prognostic factors for breast cancer metastasis and survival. *Seminars in Radiation Oncology*, 12, 319–328.
- Gershenson, D.M., Deavers, M., Diaz, S., Tortolero-Luna, G., Miller, B.E., Bast, R.C., et al. (1999).

Martha Weinar, MS, RN, is a nurse coordinator for the Risk Evaluation Program in Abraham Cancer Center at the University of Pennsylvania in Philadelphia, and Debra Mercy, MS, CRNP, AOCN®, is a breast cancer specialist and adult nurse practitioner at Saint Alphonsus Regional Medical Center in Boise, ID.

Digital Object Identifier: 10.1188/04.ONF.35-36

- Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. *Clinical Cancer Research*, 5, 4053–4058.
- Jass, J.R. (2000). Familial colorectal cancer: Pathology and molecular characteristics. *Lancet Oncology*, 1, 220–226.
- Lee, J.I., Soria, J.C., Hassan, K.A., El-Naggar, A.K., Tang, X., Liu, D.D., et al. (2001). Loss of PTEN expression as a prognostic marker for tongue cancer. *Archives of Otolaryngology*, 127, 1441–1445.
- Levine, E.A., Holzmayer, T., Bacus, S., Mechtner, E., Mera, R., Bolliger, C., et al. (1997). Evaluation of newer prognostic markers for adult soft tissue sarcomas. *Journal of Clinical Oncology*, 12, 3249–3257.
- Lo Coco, F., De Santis, S., Esposito, A., Divona, M., & Diverio, D. (2002). Molecular monitoring of hematologic malignancies: Current and future issues. *Seminars in Hematology*, 39(2, Suppl. 1), 14–17.
- Mehta, K.U., Goldfarb, M.A., & Zinterhofer, L.J. (2002). Absent p53 protein in colorectal tumor cells reflects poor survival. *Journal of Applied Research*, 2, 169–174.
- Onida, F., Ball, G., Kantarjian, H.M., Smith, T.L., Glassman, A., Albitar, M., et al. (2002). Characteristics and outcomes of patients with Philadelphia chromosome negative, BCR/ABL negative chronic myelogenous leukemia. *Cancer*, 15, 1673–1684.
- Pisani, A.L., Barbuto, D.A., Chen, D., Ramos, L., Lagasse, L.D., & Karlan, B.Y. (1995). Her-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. *Obstetrics and Gynecology*, 85(5, Pt. 1), 729–734.
- Ring, B.Z., & Ross, D.T. (2002). Microarrays and molecular markers for tumor classification. *Genome Biology*, 3(5), comment 2005.
- Tammemagi, M.C., McLaughlin, J.R., Mullen, J.B.M., Bull, S.B., Johnston, M.R., Tsao, M., et al. (2000). A study of smoking, p53, tumor suppressor gene alterations and non-small cell lung cancer. *Annals of Epidemiology*, 10, 176–185.
- The Genomic Era**
- Aeressens, J., Armstrong, M., Gilissen, R., & Cohen, N. (2001). The human genome: An introduction. *Oncologist*, 6, 100–109.
- Collins, F., & McKusick, V.A. (2001). Implications of the human genome project for medical science. *JAMA*, 285, 540–544.
- Collins, F.S., & Guttmacher, A.E. (2001). Genetics moves into the medical mainstream. *JAMA*, 286, 2322–2324.
- Fey, M.F. (2002). Impact of the human genome project on the clinical management of sporadic cancers. *Lancet Oncology*, 3, 349–356.
- Gibson, B.C. (2001). Debate. Will the human genome project have any impact on nursing? *Nursing Times*, 97(12), 22–28.
- Greco, K.E. (2000). Cancer genetics nursing: Impact of the double helix. *Oncology Nursing Forum*, 27(Suppl. 9), 29–36.
- Guttmacher, A.E., & Collins, F.S. (2002). Genomic medicine—A primer. *New England Journal of Medicine*, 347, 1512–1520.
- Hanash, S.M., Bobek, M.P., Rickman, D.S., Williams, T., Rouillard, J.M., Kuick, R., et al. (2002). Integrating cancer genomics and proteomics in the post-genome era. *Proteomics*, 2, 69–75.
- Kovvali, G., Shiff, S., Telang, N., Das, K., Kohgo, Y., Narayan, S., et al. (2003). Carcinogenesis: The more we seek to know the more we need to know—Challenges in the post genomic era. *Journal of Carcinogenesis*, 2(1), 1–5.
- Loud, J.T., Peters, J.A., Fraser, M., & Jenkins, J. (2002). Applications of advances in molecular biology and genomics to clinical cancer care. *Cancer Nursing*, 25, 110–122.
- Olopade, O.I. (1997). The human genome project and breast cancer. *Women's Health Issues*, 7, 209–214.
- Weil, J. (2002). Genetic counseling in the era of genomic medicine. *EMBO Reports*, 3, 590–593.
- Zhang, W., Labordé, P.M., Coombes, K.R., Berry, D.A., & Hamilton, S.R. (2001). Cancer genomics. *Clinical Cancer Research*, 7, 2159–2167.